Sirolimus: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
CONITEC (Brazil), G-BA (Germany) and HAS (France), among others, recommended or restricted sirolimus, while AWMSG (Wales) did not recommend it.
CONITEC (Brazil) has been easier on sirolimus than on its own caseload: it refused 0 of 5 decisive submissions here (0%), against a base rate of 44% across everything it has assessed.
The file has been open for more than a decade: 22.4 years separate the first record, 21 May 2003 at HAS (France), from the most recent, 21 Oct 2025 at CONITEC (Brazil).
No assessment is on file from PBAC (Australia), TLV (Sweden) and CIPM (Spain), each among the eight highest-volume agencies here.
Not every gap is a refusal: for sirolimus, 1 submission was never made and 3 were withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 8 of 25 records date from 2023 or later.
4 distinct indication wordings are recorded for sirolimus by the agencies that label one in English (AWMSG, NICE and SMC).
HAS (France) was first to assess sirolimus, on 21 May 2003; NYE METODER (Norway) did not open a file until 22 Sep 2024 — an unusually long tail of 21.3 years between the earliest and latest system to look at it.
The record arrives in waves: 5 separate years each carry two or more decisions, spread across 13 years in total.
5 of the 8 agencies here assessed sirolimus more than once, CONITEC (Brazil) most often at 7 entries — repeat review is the norm for this molecule rather than the exception.
8 of the 18 agencies in this archive hold a record for sirolimus.
The full ledger for sirolimus reads 14 recommended, 3 other, 2 withdrawn and 1 deferred to NICE, with 5 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| SMC (Scotland) | 13 Jan 2025 | For the treatment of adult and paediatric patients aged 6 and above with facial angiofibroma (facial AF) associated with tuberous sclerosis complex (TSC). | accepted | source |
| AWMSG (Wales) | 22 Oct 2024 | Treatment of facial angiofibroma associated with tuberous sclerosis complex in adults and paediatric patients aged 6 yea… | excluded, NICE appraised | source |
| NYE METODER (Norway) | 22 Sep 2024 | Behandling av facial angiofibrom forbundet med tuberøs sklerose-kompleks hos voksne og pediatriske pasienter i alderen 6… | decision recorded | source |
| NICE (England) | 22 May 2024 | NICE TA972 | terminated appraisal | source |
| HAS (France) | 3 Nov 2010 | Listing (Transparency Committee) | ASMR V | source |
20 further decisions for sirolimus, across 6 agencies, are not shown here. They include the most recent record on file, 21 Oct 2025 from CONITEC (Brazil); its outcome is in the subscriber dataset. They link to 12 further source documents.
Related molecules
- adalimumab — same ATC class L04A — Immunosuppressants
- upadacitinib — same ATC class L04A — Immunosuppressants
- secukinumab — same ATC class L04A — Immunosuppressants
- tocilizumab — same ATC class L04A — Immunosuppressants
- ustekinumab — same ATC class L04A — Immunosuppressants
- infliximab — same ATC class L04A — Immunosuppressants
Coverage: 25 decisions for sirolimus from 8 agencies, 2003 to 2025. Data to 7 Sep 2026. ATC class L04A — Immunosuppressants. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.